Commentary on prevention of cardiovascular complications in diabetes mellitus as novel inidicationfor Diabeton MR
Current article presents commentary on official inclusion of cardiovascular prophylaxis in indications for Diabeton MR therapy. The paper features extensive review of data from ADVANCE (Action in Diabetes and Vascular Disease: PretarAx and DiamicroN Modified Release Controlled Evaluation) trial and...
Guardado en:
Autor principal: | Olga Konstantinovna Vikulova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7350b0a553df402f90fc530ba2fec613 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Russian Association of Endocrinologists about the introduction of Diabeton MR (60 mg tablets)
por: Editorial team Diabetes Mellitus
Publicado: (2011) -
Influence of intensive glycemic control on development and progression of diabetic nephropathy in patients with type 2 diabetes mellitus (based on results from ADVANCE study)
por: Inna Igorevna Klefortova
Publicado: (2012) -
Targeting risk factors: a feasible way for prevention of vascular complications in type 2 diabetes mellitus
por: Irina Vladimirovna Kononenko, et al.
Publicado: (2012) -
Tasks and objectives of the ADVANCE study. Design of the study. Rationale for the use of diabeton MB
por: Olga Mikhailovna Smirnova
Publicado: (2009) -
AP control of as the most efficacious tool for the prevention of cardiovascular complications in patients with type 2 diabetes mellitus
por: Yury Alexandrovich Karpov
Publicado: (2009)